GWAS针对COVID-19的药物再利用

Health Biotechnology and Biopharma Pub Date : 1900-01-01 DOI:10.22034/HBB.2020.01

Mohammad Afzal, S. Sardari, S. Sikandar, Imran Afzal

{"title":"GWAS针对COVID-19的药物再利用","authors":"Mohammad Afzal, S. Sardari, S. Sikandar, Imran Afzal","doi":"10.22034/HBB.2020.01","DOIUrl":null,"url":null,"abstract":"This note is prepared by the authors of a recent publication on shared genetic architecture of drug response based on summary statistics from genome-wide association studies (GWAS) to propose a drug repurposing approach for the treatment of coronavirus COVID-19. The authors proposed that in silico studies may be preceded by analyzing shared genetic architecture of drug response based on existing GWAS. © 2020, Health Biotechnology and Biopharma.","PeriodicalId":288173,"journal":{"name":"Health Biotechnology and Biopharma","volume":"56 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Drug repurposing against COVID-19 by GWAS\",\"authors\":\"Mohammad Afzal, S. Sardari, S. Sikandar, Imran Afzal\",\"doi\":\"10.22034/HBB.2020.01\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"This note is prepared by the authors of a recent publication on shared genetic architecture of drug response based on summary statistics from genome-wide association studies (GWAS) to propose a drug repurposing approach for the treatment of coronavirus COVID-19. The authors proposed that in silico studies may be preceded by analyzing shared genetic architecture of drug response based on existing GWAS. © 2020, Health Biotechnology and Biopharma.\",\"PeriodicalId\":288173,\"journal\":{\"name\":\"Health Biotechnology and Biopharma\",\"volume\":\"56 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1900-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Health Biotechnology and Biopharma\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.22034/HBB.2020.01\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Health Biotechnology and Biopharma","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.22034/HBB.2020.01","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Drug repurposing against COVID-19 by GWAS

This note is prepared by the authors of a recent publication on shared genetic architecture of drug response based on summary statistics from genome-wide association studies (GWAS) to propose a drug repurposing approach for the treatment of coronavirus COVID-19. The authors proposed that in silico studies may be preceded by analyzing shared genetic architecture of drug response based on existing GWAS. © 2020, Health Biotechnology and Biopharma.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Health Biotechnology and Biopharma

CiteScore

0.60

自引率

0.00%

发文量